Drug DevelopmentRAPP continues working on the development of a long-acting injectable formulation of RAP-219 as the first potential anti-seizure medication in a depot formulation.

Market PotentialThere are ~1.8MM adult focal epilepsy patients in the U.S. and ~30-40% are refractory to ≥2 ASMs representing a large market.

Therapeutic ExpansionBeyond epilepsy, Rapport is also developing RAP-219 for neuropathic pain and acute mania associated with bipolar disorder, representing significant upside potential.

Bears Say

Clinical Trial LimitationsThe FDA placed a clinical hold on the IND for the Ph. IIa trial of RAP-219 in diabetic peripheral neuropathic pain.

Regulatory IssuesIND application for Phase IIa trial of RAP-219 in diabetic peripheral neuropathic pain placed on clinical hold by the FDA.

Study Design ConcernsThe Phase IIa study is open-label and will enroll just 20 patients, which may limit the robustness of efficacy data.

---

Financials

Annual

Income Statement >

RAPP FAQ

What was Rapport Therapeutics, Inc.’s price range in the past 12 months?

Rapport Therapeutics, Inc. lowest stock price was $16.55 and its highest was $29.74 in the past 12 months.

What is Rapport Therapeutics, Inc.’s market cap?

Currently, no data Available

When is Rapport Therapeutics, Inc.’s upcoming earnings report date?

Rapport Therapeutics, Inc.’s upcoming earnings report date is Nov 07, 2024 which is 16 days ago.

How were Rapport Therapeutics, Inc.’s earnings last quarter?

Rapport Therapeutics, Inc. released its earnings results on Aug 08, 2024. The company reported -$1.7 earnings per share for the quarter, missing the consensus estimate of -$0.6 by -$1.1.

Is Rapport Therapeutics, Inc. overvalued?

According to Wall Street analysts Rapport Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rapport Therapeutics, Inc. pay dividends?

Rapport Therapeutics, Inc. does not currently pay dividends.

What is Rapport Therapeutics, Inc.’s EPS estimate?

Rapport Therapeutics, Inc.’s EPS estimate is -$0.56.

How many shares outstanding does Rapport Therapeutics, Inc. have?

Rapport Therapeutics, Inc. has 36,576,458 shares outstanding.

What happened to Rapport Therapeutics, Inc.’s price movement after its last earnings report?

Rapport Therapeutics, Inc. reported an EPS of -$1.7 in its last earnings report, missing expectations of -$0.6. Following the earnings report the stock price went up 2.868%.

Which hedge fund is a major shareholder of Rapport Therapeutics, Inc.?

Among the largest hedge funds holding Rapport Therapeutics, Inc.’s share is Perceptive Advisors LLC. It holds Rapport Therapeutics, Inc.’s shares valued at 17M.

---

Rapport Therapeutics, Inc. Stock Smart Score

Unlock Smart Score

Analyst Consensus

Strong Buy

Average Price Target:
$38.50 (83.77% Upside)

Blogger Sentiment

Bullish

RAPP Sentiment 100%
Sector Average 70%

Top Smart Score Stocks >

Company Description

Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

---

RAPP Stock 12 Month Forecast

Average Price Target

$38.50

▲(83.77% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","25":"$25","31":"$31","37":"$37","43":"$43"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,25,31,37,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Aug<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.62,25.95692307692308,27.293846153846154,28.630769230769232,29.96769230769231,31.304615384615385,32.64153846153846,33.97846153846154,35.315384615384616,36.652307692307694,37.98923076923077,39.326153846153844,40.66307692307693,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.62,25.68769230769231,26.755384615384617,27.823076923076925,28.89076923076923,29.958461538461542,31.026153846153846,32.09384615384616,33.16153846153846,34.22923076923077,35.29692307692308,36.364615384615384,37.432307692307695,{"y":38.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.62,25.41846153846154,26.216923076923077,27.015384615384615,27.813846153846153,28.61230769230769,29.410769230769233,30.20923076923077,31.00769230769231,31.806153846153848,32.604615384615386,33.403076923076924,34.20153846153846,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.19,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.19,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.19,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.19,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.19,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.19,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.19,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.44,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":23.93,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.08,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.33,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.8,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Best Analysts Covering RAPP

1 Year

Andrew TsaiJefferies

1 Year Success Rate

1/2 ratings generated profit

1 Year Average Return

+13.55%

reiterated a buy rating 2 months ago

Copying Andrew Tsai's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +13.55% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing